Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
Injection site very sore; generalized achiness; muscle pain; runny nose; sneezing; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 51-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 15-JUL-2025 11:30, the patient received the 2nd dose of Shingrix (left arm). On 15-JUL-2025 19:45, less than a day after receiving Shingrix, the patient experienced injection site pain (Verbatim: Injection site very sore), generalized aching (Verbatim: generalized achiness), muscle pain (Verbatim: muscle pain), runny nose (Verbatim: runny nose) and sneezing (Verbatim: sneezing). The outcome of the injection site pain, generalized aching, muscle pain, runny nose and sneezing were not resolved. It was unknown if the reporter considered the injection site pain, generalized aching, muscle pain, runny nose and sneezing to be related to Shingrix. It was unknown if the company considered the injection site pain, generalized aching, muscle pain, runny nose and sneezing to be related to Shingrix. Additional Information: GSK Receipt Date: 16-JUL-2025 The reporter is the patient who received his second dose of Shingrix yesterday and at 7:45 pm he developed generalized achiness, muscle pains, injection site very sore, runny nose, and sneezing. Then at 2:30 am his body aches became severe. The reporter stated that he did not have a fever, and all of the symptoms were persisting.